Markets:

Overview

News

Currencies

International

Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

7.065 +0.335 (+4.98%)

Streaming Delayed Price Updated: 12:05 PM EDT, Jun 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Taysha Gene Plans Protocol Amendment After Patient Death In Gene Therapy Trial ↗

January 27, 2022

Taysha Gene Therapies Inc (NASDAQ: TSHA) reported

Via Benzinga

Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of β-Hexosaminidase A Enzyme Activity in Patients With GM2 Gangliosidosis

January 27, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 20, 2022

Gainers TCR2 Therapeutics (NASDAQ:TCRR) s...

Via Benzinga

Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 06, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

January 19, 2022

During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

January 06, 2022

On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this...

Via Benzinga

Stocks Hitting New 52-Week Lows Today ↗

January 03, 2022

On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...

Via Benzinga

Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event

January 03, 2022

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy

December 28, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus ↗

December 26, 2021

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key...

Via Talk Markets

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year ↗

December 26, 2021

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating...

Via Benzinga

Taysha Gene Therapies Added to the ICE Biotechnology Index

December 23, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design

December 22, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease

December 16, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021 ↗

December 16, 2021

Upgrades According to B of A Securities, the prior rating for Generac Holdings Inc (NYSE:

Via Benzinga

Taysha Gene Therapies Added to the Nasdaq Biotechnology Index

December 15, 2021

From Taysha Gene Therapies

Via Business Wire

The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré ↗

December 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome...

Via Benzinga

Taysha Gene's Epilepsy Candidate Shows Encouraging Action In Preclinical Studies ↗

December 07, 2021

Taysha Gene Therapies Inc (NASDAQ: TSHA) announced a late-breaking abstract and poster presentation on preclinical data for TSHA-105 for SLC13A5-related epilepsy....

Via Benzinga

Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency

December 06, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies, Inc. (TSHA) Q3 2021 Earnings Call Transcript ↗

November 11, 2021

TSHA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 10, 2021

From Taysha Gene Therapies

Via Business Wire

Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences

November 08, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10

November 03, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies Announces Publication of Positive Proof-of-Concept Preclinical Data for an AAV-mediated UBE3A Gene Replacement Approach Demonstrating Therapeutic Potential for The Treatment of Angelman Syndrome in the Journal JCI Insight

October 25, 2021

From Taysha Gene Therapies

Via Business Wire

Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit

October 21, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Neuropathy (GAN) in Partnership with GeneDx as well as a Collaboration with Hereditary Neuropathy Foundation and Charcot-Marie-Tooth Association Centers of Excellence

October 13, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-106 for the Treatment of Angelman Syndrome

October 12, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research Collaboration with UTSW to Develop Next-Generation Construct for CLN7 and a Grant Award to Batten Hope

October 05, 2021

From Taysha Gene Therapies

Via Business Wire

Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis

September 29, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies to Participate in Upcoming October Investor Healthcare Conferences

September 28, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.